In a cohort of 200 IDH1 wild-type GBM patients, an integrative model based on a panel of radiomic features, clinical profiles, and protein expressions (CIC, PIK3R1, FUBP1, p53, vimentin) obtained an AUC of 78.24% in predicting survival outcomes [64]. The gene discussed is IDH1; the disease is glioblastoma.